QuidelOrtho Corporation (QDEL)
| Market Cap | 818.34M |
| Revenue (ttm) | 2.73B |
| Net Income (ttm) | -1.13B |
| Shares Out | 68.08M |
| EPS (ttm) | -16.69 |
| PE Ratio | n/a |
| Forward PE | 5.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,466,414 |
| Open | 12.24 |
| Previous Close | 12.29 |
| Day's Range | 11.74 - 12.37 |
| 52-Week Range | 10.86 - 38.99 |
| Beta | 0.92 |
| Analysts | Hold |
| Price Target | 28.25 (+135.03%) |
| Earnings Date | May 5, 2026 |
About QDEL
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or... [Read more]
Financial Performance
In 2025, QuidelOrtho's revenue was $2.73 billion, a decrease of -1.89% compared to the previous year's $2.78 billion. Losses were -$1.13 billion, -44.84% less than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for QDEL stock is "Hold." The 12-month stock price target is $28.25, which is an increase of 135.03% from the latest price.
News
Understanding and Addressing Syphilis Trends - and What's Being Missed
SAN DIEGO, April 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 57 of its Science Bytes podcast, focusing on evolving sy...
TTP Group Announces the Sale of LEX Diagnostics
CAMBRIDGE, England--(BUSINESS WIRE)--TTP today announced the acquisition by QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, of LEX Diagnostics Limited, a UK-based mole...
QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics
– Marks a Milestone in QuidelOrtho's Plans to Accelerate Growth in Point-of-Care Molecular Diagnostics – – Expands Portfolio with Ultra-Fast PCR Platform Designed to Deliver Results in Approximately T...
QuidelOrtho Stock Sinks To 52-Week Low - Here's Why
The diagnostic healthcare products maker reported preliminary unaudited revenue in the range of $615 million to $620 million for the first quarter, compared to the consensus of $680.59 million.
QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance
SAN DIEGO, April 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, today announced preliminary unaudited revenu...
Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer
SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Na...
QuidelOrtho Transcript: 47th Annual Raymond James Institutional Investor Conference
The conference highlighted strong recurring revenue, global market leadership, and robust financial performance, with a focus on innovation, new product launches, and the Lex Diagnostics acquisition. Guidance points to margin expansion, significant cash flow growth, and continued operational improvements.
Faster Cardiac Answers with High‑Sensitivity Troponin
SAN DIEGO, Feb. 19, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 56 of its Science Bytes podcast, featuring Dr. Lindy Carl...
QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference
SAN DIEGO, Feb. 18, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced that members of it...
QuidelOrtho Earnings Call Transcript: Q4 2025
2025 saw strong mid-single-digit growth, margin expansion, and $2.73B in revenue, with Labs and Triage businesses leading. 2026 guidance projects up to $2.9B in revenue, further margin gains, and continued cost savings, while respiratory and China remain key uncertainties.
QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results
― Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 ― ― Continued growth and margin expansion expected in FY26; free cash flow expected to i...
QuidelOrtho Receives Excellence Services Label in EMEA and Two Stevie® Awards
– First medical device company to receive excellence recognition in accordance with ISO 23592 – Gold Stevie® Award for Customer Service Success – Bronze Stevie® Award for AI & Tech Focused Digital Tra...
Strengthening the blood supply: Awareness, challenges and donor impact
SAN DIEGO, Jan. 22, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released episode 55 of its Science Bytes podcast, featuring Michelle Mulle...
QuidelOrtho to Report Fourth Quarter and Full-Year 2025 Financial Results
SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its finan...
Innovating Diagnostics and What's Next
SAN DIEGO , Dec. 18, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 54 of its Science Bytes podcast, featuring Jonathan Sieg...
QuidelOrtho Transcript: Citi Annual Global Healthcare Conference 2025
Stock volatility after Q3 was driven by technical and guidance factors, but core business segments showed solid growth and stability. Margin and cash flow improvements are on track, with new product approvals and cost savings initiatives supporting long-term targets.
QuidelOrtho Transcript: Evercore ISI 8th Annual HealthCONx Conference
Solid Q3 performance and margin expansion are driven by cost reductions and portfolio optimization. Growth is expected in labs, immunohematology, and point of care, with LEX set to replace SAVANNA as the molecular platform. Margin and cash flow improvements are targeted through 2027.
QuidelOrtho To Participate In Upcoming Investor Conferences
SAN DIEGO , Nov. 24, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global leader of in vitro diagnostics, announced today that members of its management team will part...
The Power of Prevention: Detecting Diabetes Before It Strikes
SAN DIEGO , Nov. 20, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 53 of its Science Bytes podcast, featuring Qian Ding, MD...
QuidelOrtho Earnings Call Transcript: Q3 2025
Q3 saw 5% organic sales growth (excluding COVID and donor screening), with adjusted EBITDA margin up to 25% and significant cost savings. 2025 guidance was narrowed, maintaining a 22% margin target and $2.00–$2.15 EPS, while a $701M goodwill impairment was recorded.
QuidelOrtho Reports Third Quarter 2025 Financial Results
― Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum ― ― Successful completion of debt refinanci...
QuidelOrtho Receives FDA 510(k) Clearance for VITROS™ Immunodiagnostic Products hs Troponin I Assay
Clearance expands menu and enables high-sensitivity troponin I measurement to aid in the diagnosis of myocardial infarction SAN DIEGO , Nov. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administrati...
Informatics Illuminated: Science Bytes Podcast Explores the Power Behind Smarter Diagnostics
SAN DIEGO , Oct. 23, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 52 of its Science Bytes podcast, featuring George Wiersc...
QuidelOrtho to Report Third Quarter 2025 Financial Results
SAN DIEGO , Oct. 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its fina...
QuidelOrtho Showcases Leadership in Transfusion Medicine at AABB 2025
FDA-approved MTS™ DAT Card and advanced ORTHO VISION™ Platform highlight the company's continued leadership in transfusion medicine SAN DIEGO , Oct. 16, 2025 /PRNewswire/ -- QuidelOrtho Corporation (N...